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Abstract: Cytokines and growth factors in colostrum and mature milk may play an important role in
infant immune maturation, and may vary significantly between populations. We aimed to examine
associations between environmental and maternal factors, and human milk (HM) cytokine and
growth factor levels. We recruited 398 pregnant/lactating women in the United Kingdom, Russia, and
Italy. Participants underwent skin prick testing, questionnaire interview, and colostrum and mature
milk sampling. HM cytokine and growth factor levels were quantified by electro-chemiluminescence.
We found significant geographical variation in growth factor levels, but no evidence of variation
between sites in cytokine detectability. There was an inverse correlation between time of milk
sampling and growth factor levels in colostrum for Hepatocyte Growth Factor (HGF) and TGFβ1 and
TGFβ3, but not TGFβ2, and levels were significantly higher in colostrum than mature milk for all
growth factors. The kinetics of decline were different for each growth factor. Cytokines were present
at much lower levels than growth factors, and the decline over time was less consistent. HM growth
factors and cytokine levels vary between populations for unknown reasons. Levels of HM mediators
decline at different rates postpartum, and these findings suggest specific biological roles for HM
growth factors and cytokines in early postnatal development.
Keywords: colostrum; human milk; immune modulators; immunologically active molecules;
cytokines; growth factors; environmental influence
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1. Introduction
Human milk (HM) is usually the first source of nutrition for a newborn, and an important factor
assisting infants in the first months of life, not only as a nutrition source but also as a manner of
adapting infants to their extra-uterine environment. Breastfeeding is known to have positive short- and
long-term effects on child health, although its influence on allergy development is still debatable [1].
There have been few attempts to investigate relationships between maternal and environmental factors
and immune active profiles of HM. Data from a variety of studies suggest that factors such as country
of maternal origin, diet, exercise, and exposure to smoke or farming environment in early life may
influence colostrum and HM constituents [2–22].
It has been shown that Hepatocyte Growth Factor (HGF) is known to regulate vascular endothelial
growth factor (VEGF) production from endothelial cells [23] and complements VEGF biological activity
in the infant gut [24]. HGF levels in maternal serum change throughout pregnancy, peaking at 30 to
40 weeks of gestation and then decreasing upon delivery [25]. As levels of HGF are 20 to 30 times
higher in colostrum than in maternal serum [26] it is reasonable to propose that HGF is actively
excreted into HM in order to support infant’s gut immunity maturation and growth.
Inverse relationships between the risk of atopic diseases, associated with T-helper lymphocyte
type 2 (TH2) immune response, and indicators of early-life exposure to infections, such as high birth
order or sibship size, early attendance at day care, and early exposure to pets or other animals are
well described [27]. The “hygiene hypothesis” remains one of the most popular current hypotheses on
early-life exposures and allergy risk [28]. It has been suggested that farming environment [6], higher
bacterial exposure [7], or maternal country of origin [5] may have significant impacts on HM immune
composition, and such effects on HM composition may be an important pathway through which early
variations in microbial exposures influence risk of allergy development.
Our study aimed to prospectively investigate the relationship between maternal and
environmental factors and levels of HGF, Transforming Growth Factor beta (TGFβ)1,2,3 and
detectability of TH1 and TH2 cytokines using colostrum and HM samples collected from birth cohorts
in three regions; the UK, eastern Europe, and continental Europe.
2. Materials and Methods
2.1. Study Setting, Eligibility Criteria, and Ethics
The investigations and sample collection have been conducted following ethical approval by
Ethics committee in three countries participating in the study: West London Rec 3 (UK) (Ref. number
10/H0706/32) and all paperwork has been completed according to the hospital R&D Joint Research
Office (UK) (JROSM0072) policy; Ethical Committee of the Azienda Ospedaliera di Verona (Italy)
(approval No. 1288), and Moscow Institute of Paediatrics and Child Health of Ministry of Health of
Russian Federation (Russia) (approval No. 1-MS/11). All women provided written informed consent.
Women were enrolled at antenatal and postnatal units of three participating centres—St. Mary’s
Hospital, London, UK; Maternity Hospital No. 1, Moscow, Russia; G.B. Rossi Hospital, Verona, Italy.
Inclusion criteria for the study were: healthy term infants and their mothers intending to breastfeed
and willing to comply with the study procedures.
Exclusion criteria were: maternal immunosuppressive treatment during lactation, or severe
illness; infants with a major birth defect, admitted to neonatal intensive care, other severe illness, born
prematurely (<37 weeks gestation), or with low birth weight (<2nd centile).
2.2. Medical Records and Interview
Following enrolment, participants underwent allergy skin prick testing (SPT) and answered
a 10 min interview-based questionnaire regarding their medical history. Exposure variables recorded
were selected based on a detailed review of known determinants of HM composition [29]. Information
collected from the recruited women included parity; age; mode of delivery; details of residence
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environment, such as mould presence at home, regular contact with animals and/or pets at home;
exposure to tobacco smoke (smoker or living in household with smoker or self-reported passive
smoker); any reports of infections during pregnancy. We also obtained information on maternal dietary
preferences—fish, fresh fruit, and probiotic intake. Participant medical records were reviewed by study
personnel to extract relevant health information which was not available from questionnaires, prior to
breast milk analysis. SPT was undertaken using the following solutions: Histamine 1% Positive Control,
Glycerol Negative Control, House Dust Mite (Dermatophagoides pteronyssinus), Cat (Felix domesticus),
Grass Pollen, Birch pollen, Peanut, Hazelnut, Egg (all from Stallergenes, SA 92160 Anthony, France),
and Cow’s milk (ALK-Abello, Hø´rsholm, Denmark). SPT was performed by standard technique using
1 mm lancets (ALK-Abello, Hø´rsholm, Denmark), and were read at 15 min. Allergic sensitization was
defined as a wheal ≥3 mm to at least one allergen, in the context of a wheal ≥3 mm to histamine and
no wheal to the negative control.
2.3. Human Milk Sampling
Participants were given sterile tubes to collect their own colostrum (once in the first 6 days
of life) and mature HM (once at 4–6 weeks postpartum). Local site investigators and participating
mothers were asked to collect colostrum or milk at the first morning breastfeed, by manual expression
(colostrum) or collecting the drip (mature milk) from the contra-lateral breast during feeding [15].
Colostrum samples were frozen at −50 ◦C to −80 ◦C within 12 h of collection. HM samples were
collected at home, stored in the fridge for not longer than 4 h, and transported to participating units by
study staff, and frozen at 50 ◦C to−80 ◦C within 12 h of collection. It has been previously demonstrated
that storage for 6 months at either −20 ◦C or −80 ◦C did not influence the concentration of immune
active factors in human milk [30]. After thawing, samples were centrifuged at 1500× g for 15 min
at 4 ◦C. The lipid layer was removed with a pipette and aqueous fraction was analysed for immune
modulators [31]. All milk samples were transported to London at −70 ◦C where the samples were
stored at −80 ◦C until analysis.
2.4. Electro-Chemiluminescence
We used electro-chemiluminescence to measure immune mediators in colostrum and breast milk
samples for Th1 and Th2 cytokines, HGF, and TGFβ1-3 (MesoScale Discovery, Rockville, MD, USA).
Laboratory experiments were run according to manufacturer’s protocol, using an eight-point standard
curve. No dilution was used for Th1 and Th2 cytokines and HGF, and 1:2 dilution for TGFβ assays,
following pilot experiments which showed that TGFβ2 levels in undiluted milk samples were often
greater than the upper limit of detection. Assays were run in duplicate, and mediator levels were
excluded where the CV was >25%—Median (IQR) levels and assay detection limits for each immune
mediator studied are shown in Table A1.
2.5. Protein Analysis
We used turbidimetry to assess total protein concentration in colostrum samples (Abbott Architect
Analyser C8000, Abbott, Abbott Park, IL, USA). For turbidimetry colostrum, proteins were denatured
by benzethonium chloride, then measured at 404 nm. Pilot experiments determined that a 1:30 onboard
dilution was needed to bring the colostrum protein concentration to within the linear measurement
range of the Architect Analyser (3–60 g/L). Prior to protein analysis samples were thawed and
centrifuged at 3000× g for 15 min at 4 ◦C. Next, 300 µL of supernatant were carefully transferred to the
tubes and loaded into the Architect device for the analysis.
2.6. Statistical Analysis
Maternal factors and levels/detection of cytokines and growth factors were summarized using
standard descriptive statistics. As outcome variables were not normally distributed, non-parametric
tests such as the Mann–Whitney U-test, were used to compare independent observations of different
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populations for unadjusted analyses. All growth factors have been presented as a continuous
variable (pg/mL), whilst data on cytokines were transformed into a binary variable (detectable
versus undetectable). Since concentration of growth factors and cytokines were assayed twice
(in both colostrum and breast milk) for many participants, we used a mixed-effect regression model to
account for the absence of independence between those two measures and to evaluate a broad range
of variables. Continuous data with non-parametric distribution were log-transformed for inclusion in
regression models.
Model selection was based on major approaches such as Akaike and Bayesian information criteria.
Difference between groups effects (maternal and environmental factors) as well as within subject effects
were evaluated using multilevel mixed-effect regression model. Factors and covariates included in the
models were: parity, maternal sensitisation, maternal age, site of collection, mode of delivery—vaginal
birth/caesarean section, mould presence at home, pets at home or regular contact; exposure to tobacco
smoke (i.e., maternal active smoking or living in household with smoker or self-reported passive
smoker) at recruitment; at least one self-reported maternal infection during pregnancy; maternal
diet—fish intake at least once per week versus less often; daily fresh fruit versus less often; daily
probiotic versus none/less often.
As models were used for the statistical analysis, the sample size reduced slightly, due to incomplete
data for one or more variables included in the multivariate model in 56 individuals. This explains
discrepancy in colostrum numbers. Reduced numbers were included in analysis of human milk
samples, due to missing samples. Milk samples were missing due to cessation of breastfeeding before
this time, due to mother’s not supplying a sample within the four to six week time window for
sampling, and due to loss to follow up/not contactable women.
Outcomes assessed were levels of HGF, TGFβ1, TGFβ2, TGFβ3, and cytokine detectability.
Relationship between corrected growth factor levels and time (measured as HGF/Protein,
TGFβ1/Protein, TGFβ2/Protein, and TGFβ3/Protein in pg/g) was assessed using the Spearman
rank correlation coefficient. Results were considered significant when p-values were reported at a level
less than 0.05. Bonferroni correction was used in mixed models analyses to control for false discovery.
3. Results
3.1. Study Population
Total of 481 mothers were recruited into the study from June 2011 to March 2012 from the birth
centres and antenatal and postnatal units of secondary and tertiary hospitals from three countries,
located in Northern Europe, Eastern Europe, and the Mediterranean area. Of 481 women, 398 (UK
n = 101, Russia n = 221, Italy n = 76) provided samples and were included in this study. The 83 mothers
unwilling or unable to provide colostrum samples postnatally were not evaluated further.
Demographic data of the participants is presented in Table 1. Significant differences between
groups were seen for most variables recorded. Maternal age (highest in Italy), maternal allergic
sensitization (highest in UK), rate of Caesarean section (highest in UK), tobacco smoke exposure
(highest in Russia), antenatal infections (highest in Italy), and time of colostrum collection (earlier in
Russia than other sites) all differed significantly. There was also weak evidence for differences in parity
and birth weight across centres). Infant sex did not significantly differ across sites.
3.2. Association between Collection Time and Colostrum/Breast Milk Composition
Among the environmental and maternal factors analysed we found time of milk sample collection
postpartum to have the most significant influence on growth factor levels, and a mixed effect on
cytokine detectability. A significant decline over time in colostrum was seen for HGF, TGFβ1 and
TGFβ3, IL2, IL5, IL10, and IFNγ. No significant influence but similar trends were seen for most of
the other mediators (Table 2 and Figure 1). Differences between colostrum and mature milk showed
similar findings for growth factors, which were all statistically significant. For cytokine detectability
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in breast milk versus colostrum, findings were mixed and not entirely consistent with the changes
seen over time in colostrum. IL10 was more commonly detected in colostrum than in HM, but IL4 and
IFNγ were more commonly detected in HM, despite no change or a decline in detectability over time
in colostrum samples. Other cytokines showed no significant difference between colostrum and HM
(Table 2).
Table 1. Characteristics of study participants.
UK Russia Italy p-Value (ThreeCountries)
Maternal allergic sensitisation * 35/94 (37) 22/156 (14) 9/40 (23) <0.01 a
Maternal Age (years) 32.8 (4.78) 29.8 (4.45) 37.4 (5.38) <0.01 b
Vaginal Delivery 70/101 (69) 188/219 (86) 62/76 (82) <0.01 a
Male sex 54/101 (53) 118/216 (55) 41/76 (54) 0.98 a
Birth Weight (grams) 3527 (535.37) 3526 (438.97) 3328 (476.95) 0.05 b
Primiparous women 55/100 (55) 93/216 (43) 29/75 (39) 0.06 a
Household tobacco smoke exposure 30/99 (30) 135/218 (62) 25/76 (33) <0.01 a
Antenatal Infections † 16/100 (16) 61/211 (29) 29/76 (38) <0.01 a
Time of colostrum collection (hours) 58.61 (33.2) 50.03 (14.34) 57.84 (26.52) <0.01 b
a Pearson χ2 test has been used; b ANOVA test has been used. Data shown are (n/(%)) for binary variables,
and (mean (S.D.)) for continuous variables; * Defined as skin prick test wheal ≥3 mm to at least one of
a panel of common allergens; † Antenatal infection is defined as at least one self-reported maternal infection
during pregnancy.
Table 2. Relationship between time of sample collection and milk composition.
Immune
Modulator
Colostrum Composition Paired Differences between HM and Colostrumof Colostrum and Breast Milk Composition
Change
over Time β p-Value
Difference between
Colostrum and HM
over Time
β p-Value
HGF Lower −0.01 <0.001 ** Higher in colostrum −1.35 <0.001 **
TGFβ1 Lower −0.003 0.01 * Higher in colostrum −0.93 <0.001 **
TGFβ2 No change −0.003 0.12 Higher in colostrum −1.12 <0.001 **
TGFβ3 Lower −0.01 <0.001 ** Higher in colostrum −2.03 <0.001 **
IL2 Lower −0.02 0.02 * No difference 0.32 0.30
IL4 No change −0.01 0.22 Higher in HM 0.72 0.04 *
IL5 Lower −0.03 <0.001 ** No difference −0.54 0.09
IL10 Lower −0.02 <0.001 ** Higher in colostrum −1.66 <0.001 **
IFNγ Lower −0.01 0.04 * Higher in HM 1.20 <0.001 **
IL12 No change −0.01 0.12 No difference −0.11 0.73
IL13 No change −0.01 0.09 No difference 0.09 0.72
Data shown are concentration (pg/mL) for growth factors, and detectable versus not detectable for cytokines.
A multilevel mixed-effect regression model was used for all analyses, which were adjusted to the following
factors: Parity, Maternal Atopy, Maternal age, Site of collection, Mode of delivery, Mould presence at home, Pets
at home or regular contact; Exposure to tobacco smoke; At least one self-reported maternal infection during
pregnancy; Maternal diet. HM, human milk; HGF, Hepatocyte Growth Factor. * p value < 0.05; ** p value < 0.01.
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Figure 1. Unadjusted growth factors conce tratio ( g mL) in colostrum and breast milk across all
sites (overall) and at each site of collection (London, osco , and Verona). ** p value < 0.01.
3.3. Association between Collection Site and Colostrum/Breast Milk Composition
3.3.1. Growth Factors
We found a significant influence of country of residence on some growth factor concentrations
(Table 3 and Figure 2). TGFβ2 and TGFβ3 showed consistent findings in colostrum and HM
samples—levels of both factors were higher in UK and lower in Italy, with intermediate levels in
Russian women. HGF was lowest in the colostrum, but not HM, of mothers in Italy (mean log HGF
7.38, SE 0.12 in Italy; 7.98 (0.11) UK; 7.99 (0.10) Russia). TGFβ1 did not show consistent differences
bet een sites in colostrum and HM analyses, with higher levels in UK colostrum samples compared
with Italy (mean log TGFβ1 6.80 (0.07) in the UK; 6.53 (0.08) Italy); and high levels in Russian HM
samples (6.36 (0.08)) compared with Italy (5.86 (0.11)) or the UK (5.96 (0.11)). We evalu ted a number
of ther maternal factors for association with growth factor concentrations, and found weak evidence
of an association between fi h co sumption less than once a we k d higher l vels of TGFβ1 (mean
log TGFβ1 6.72 (0.06) for less than once a week; 6.57 (0.05) for more than once a week); and primiparity
with higher levels of HGF in colostrum (7.87 (0.08) for primiparous; 7.69 (0.08) for multiparous) and
HM (6.92 (0.11) for primiparous; 6.75 (0.11) for multiparous).
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Table 3. Concentration (pg/mL) of growth factors in colostrum and breast milk and exposures
associated with the levels.
Median (IQR) pg/mL Important Growth Factor Level Difference between the Groups
Colostrum
HGF 2055.31 (964–6239)
UK and Russia higher than in Italy p < 0.001
Primipara higher than Multipara p = 0.05
TGFβ1 731.534 (505–1142)
UK higher than Italy p = 0.01
Fish consumption Less than once
a week higher than At least once a week p = 0.04
TGFβ2 42,209.88 (23,847–98,597) UK higher than Russia and Italy p < 0.05
TGFβ3 1535.081 (847–3395) UK higher than Russia higher than Italy p < 0.05
Breast Milk
HGF 784.041 (508–1189) Primiparous higher than Multigravida p = 0.05
TGFβ1 493.514 (375–653) Russia higher than UK and Italy p < 0.05
TGFβ2 14,040.62 (10,080–27,262) UK higher than Russia and Italy p < 0.05
TGFβ3 279.41 (183–395) UK higher than Russia higher than Italy p < 0.05
A multilevel mixed-effect regression model was used for all analyses, which was adjusted using Bonferroni
correction, to the following factors: Parity, Maternal Atopy, Maternal age, Site (Country) of collection, Mode
of delivery—labour versus no labour, Mould presence at home, Pets at home or regular contact; Exposure to
tobacco smoke (i.e., smoker or living in household with smoker or self-reported passive smoker) at recruitment;
At least one self-reported maternal infection during pregnancy; Maternal diet—fish intake at least once per
week versus less often; daily fresh fruit versus less often; daily probiotic versus none/less often.
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Figure 2. Association between site o lection and growth factor concentrations in colostrum
and breast milk. Data sho n are ean (bold line) and 95% CI (shaded area) for log transformed
concentrations of HGF (a); TGFβ1 (b); TGFβ2 (c); and TGFβ3 (d) in the UK (red), Russia (blue), and
Italy (green). A multilevel mixed-effect regression model was used for all analyses which were adjusted
to the following factors: Parity, Maternal Atopy, Maternal age, Site (Country) of collection, Mode of
delivery, Mould presence at home, Pets at home or regular contact; Exposure to tobacco smoke, at
recruitment; At least one self-reported maternal infection during pregnancy; Maternal diet.
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3.3.2. Cytokines
Women reporting infections during pregnancy had detectable levels of IL5 less often in comparison
to mothers reporting no antenatal infections (Table 4). Smoking, type of delivery, and antenatal
infections were not related to detection of cytokines in HM or colostrum.
Table 4. Detectability of Th1 and Th2 Cytokines in Colostrum and Human Milk.
Colostrum Detectable Human MilkDetectable
Factors Associated with
Cytokines Detectability
IL2 49/342 (14%) 38/190 (20%) NA
IL4 35/342 (10%) 30/190 (16%) NA
IL5 77/342 (23%) 27/190 (14%) Antenatal infectionsOR 0.49 (95% CI 0.25–0.98)
IL10 225/342 (66%) 69/190 (36%) NA
IFNγ 66/342 (19%) 92/190 (48%) NA
IL12 63/342 (18%) 31/190 (16%) NA
IL13 86/342 (25%) 58/190 (31%) NA
NA—no association. A multilevel mixed-effect regression model was used for all analyses which were adjusted
to the following factors: Parity, Maternal Atopy, Maternal age, Site (Country) of collection, Mode of delivery,
Mould presence at home, Pets at home or regular contact; Exposure to tobacco smoke, at recruitment; At least
one self-reported maternal infection during pregnancy; Maternal diet.
3.3.3. Protein and Sodium in Colostrum
Protein in human colostrum declines over time (r = −0.42; p < 0.001) with all growth factor
levels demonstrating a significant and marked decline over time, although the slope of decline varied
between growth factors. When corrected for protein, the correlation between growth factor levels and
time of collection was inconsistent between factors, with a significant decline seen for HGF/Protein,
an increase over time seen for TGFβ1/Protein and TGFβ2/Protein, and no change over time seen for
TGFβ3/Protein. The relationship between time of colostrum collection and growth factor or growth
factor/Protein level for the four growth factors measured is shown in Table A2 and Figure 3.
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Figure 3. Effect of correcting growth factor concentrations for total protein level on the relationship 
between concentration and time. Data show nonlinear curves for unadjusted concentrations (pg/mL) 
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Figure 3. Effect of correcting growth factor concentrations for total protein level on the relationship
between concentration and time. Data show nonli ear curves for unadjusted concentrations (pg/mL)
of HGF (blue), TGFβ1 (orange), TGFβ2 (green), and TGFβ3 (pink) in colostrum in relation to time of
sampling. Correlations were explored using raw data (a); and the ratio of growth factor concentration
to protein concentration in the same sample (b). Trends in absolute and relative growth factors
concentration in colostrum change over time. All correlation coefficients were statistically significant
apart from the TGFβ3/Protein ratio in Figure 3b.
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4. Discussion
In this large prospective cohort study, we have confirmed earlier findings of significant differences
in milk composition between sites, but were not able to explain these differences through maternal
or environmental factors. We identified important differences between mediators in kinetics of
decline postpartum and these data suggest specific mechanisms controlling HM immune composition,
and support important biological roles for HM immune factors in the developing infant.
Data from a variety of studies suggest that colostrum and HM constituents may be influenced by
the country of origin and a number of environmental conditions which may differ significantly from
one location to another [3–7,32], but the cause of this difference is still unclear. Our data suggest that
HGF levels were lower in the colostrum/milk of Italian mothers and TGFβ2 and TGFβ3 were higher
in colostrum/milk of UK mothers with the same significant difference for colostral TGFβ1 (Figure 2).
Amoudruz showed that Mali women have higher levels of TGF-β1 in comparison with women born in
Sweden [5]. Peroni reported higher HM TGF-β1 in a farming compared with urban environment [6].
Tomicic found Estonian mothers have lower HM TGFβ2 than Swedish mothers [7] which the authors
suggested may be due to differences in microbial exposure. Orivuori et al. assessed HM samples
collected in four countries of continental Europe and Finland and showed TGFβ1 levels to be highest
in Finland and sIgA lowest in Germany [32]. We explored a number of maternal and demographic
variables including markers of microbial load such as maternal report of probiotic, pet, and mould
exposure, but we were not able to confirm these previous findings.
At present, we do not possess strong evidence of maternal allergic status influences on qualitative
and quantitative immunological constituents in HM. We did not find any relationship between the
levels of growth factors and/or detectability of cytokines and maternal allergy; this is in agreement
with data from other studies which found no obvious trend in HM composition of allergic mothers
compared to non-allergic [32–34].
Our data show some evidence for higher levels of HGF and TGFβ3 in the colostrum of primiparous
women. Data from some studies suggest that parity does not influence HM composition. This
borderline trend can be seen in some (but not all [3,35]) other studies [4,36,37], suggesting that higher
levels of certain immune active markers can be found in the HM of primiparous mothers, which may
be an additional mechanism to explain decreased allergy risk with an increase of birth order.
We found some evidence that fish intake during pregnancy can influence HM composition [3]—we
found higher colostrum TGFβ1 in women eating fish less than once a week. This adds to a confusing
picture, with Urwin reporting TGF-β1 levels to be highest in the colostrum of women residing in the
river and lake region of China [3], well known for high fish consumption and Hawkes not finding any
relationship between fish oil intervention and TGFβ1 levels [38]. Thus, the reasons behind differences
in the HM immunological profile between countries remain unclear. Further work should consider
genetic and gene/environment influences, as well as detailed dietary assessments, in addition to the
factors evaluated in this study. Data from So-Yeon Lee and co-authors show that breastfeeding was
found to be associated with a reduced risk of allergic sensitisation in children with CT/CC geno-type,
suggesting gene-environment interaction between the CD14C-159T polymorphism and breastfeeding
in relation to aeroallergen sensitisation [39].
It is well established that colostrum is particularly rich in immunologically active molecules and
that levels of immunological factors are lower in mature HM [6,12,40,41]. Although our study did
not involve HM collection in the same individuals over multiple timepoints, the sample size was
large enough to identify a strong relationship between time of sampling postpartum and growth
factor levels. We observed a strong relationship between growth factor levels and time postpartum
both within colostrum, and between colostrum and mature milk samples, which was independent
of geographical location. Although the difference between colostrum and mature milk composition
is well established in the literature [6,12,40,41], our finding of a rapid decline in growth factor levels
(HGF, TGFβ1, TGFβ3) and evidence for reduced detectability of cytokines (IL2, IL5, IL10, IFNγ) in
colostrum with time postpartum has not been consistently demonstrated by others. Soto-Ramirez et al.
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found none of the immune markers to correlate with the time of milk collection in a study conducted
in the USA [42]; this may be partially explained by a wide range in collection times (week one to eight)
and absence of colostral samples. In a study done in China with a narrower range of collection times,
levels of TGF-β1 and TGF-β2 decreased significantly over time [3]. Studies which do not adequately
account for variations in sampling time may explain some of the inconsistency of HM composition
and its determinants in the literature [29].
Dilution could be a potential explanation of the growth factor decline over time. During the first
week of life the infant’s volume requirements are low. Later levels of the immune active molecules
decrease as the volume and nutritional requirements of the infant increase. Immune active constituents
of colostrum and breast milk represent a minor component but one of the most biologically active
parts of HM total protein. In this study, we attempted to adjust for dilutional effects by correcting
growth factor colostrum levels for total protein level in the same sample. Correction for colostrum total
protein failed to consistently remove the relationship between factor level and time postpartum, and
highlighted significant variation between factors in the kinetics of decline. This implies active transport
of these growth factors using varied mechanisms specific to each factor. If we assume biological
relevance, then these results suggest that infants need relatively higher amounts of TGFβ1 and TGFβ2
for longer than that of TGFβ3 or HGF. TGFβ3 is significantly different from TGFβ1 and TGFβ2 in
its detailed tertiary structure of the active domain despite homology in amino acid sequence [43].
There is some evidence [43] that TGFβ3 may also have distinct functions to other TGFβ isoforms.
TGFβ3 is up-regulated by milk stasis, and induces apoptosis in mammary gland epithelium during
involution, in contrast to TGFβ1 and TGFβ2 [44]. The biological relevance of HM TGFβ is illustrated
by the observed direct correlation between the levels of TGFβ in human milk and infant serum IgA [45].
As the infant’s immune response matures there is likely to be less need for an extrinsic supply of
immune stimulants.
The main limitations of our study are first that we did not assess maternal diet using a food
frequency questionnaire, did not collect detailed information on the strain of probiotics and/or fish oil
supplements used, and did not evaluate maternal genotype as a potentially important determinant or
modulator of HM composition. This means that while we were able to explore our primary focus of
maternal and demographic factors influence on HM composition, we were not able to reliably identify
reasons for the difference in HM composition identified between sites. Second, we sampled single
colostrum and HM specimens from each subject. Our findings regarding the kinetics of growth factor
decline in colostrum and HM need to be explored further in prospective studies with longitudinal
sampling at multiple timepoints within the same participants. Third, we only made preliminary
attempts to adjust for the effect of time or milk maturity on compositional analysis. Since time
postpartum may be a surrogate for milk/breast maturity, we aimed to identify a ‘correction factor’ that
might reflect milk maturity. We did not find evidence that any growth factor concentration was related
to HM protein concentration, but further work is needed to identify markers of HM maturity in order
to control for this in compositional analysis of colostrum. Maternal body mass index (BMI) data has
not been assessed due to a difficulty in one of the participating countries. Finally, due to logistical,
funding, and sample size constraints our analysis covers only a small number of growth factors and
cytokines, so may not be generalisable to all immune factors in HM.
5. Conclusions
In this large international cohort study of HM composition, we have found an important influence
of time after birth on colostrum composition, which must be adjusted for in any further research.
Despite adjusting for this and other factors, we identified unexplained and significant variation in
HM immune composition between geographically distant populations. Overall, our data suggest that
levels of human milk mediators decline at different rates post-partum, and this may suggest that these
factors are likely to have specific biological roles in early postnatal development. An important aim
of future research should be to optimize the analysis of HM composition, accounting for maturity of
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milk, and aim to better understand the biological roles and consequences for the developing infant of
variations in HM immune composition.
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Appendix A
Table A1. Lower limit of detection values (pg/mL) for cytokines and growth factors analysis and
overall locations median concentrations for all immune active molecules (values below LLOD for all
cytokines have been transformed into 1/2 of LLOD).
Immune Active
Molecule
Median Lower Limit
of Detection
Median (IQR)
Colostrum Median (IQR) HM
IFN-γ 3.49 1.23 (0.51–3.49) 3.49 (1.54–7.8)
IL2 2.06 0.6 (0.29–1.47) 0.98 (0.23–2.06)
IL4 1.83 1.83 (0.24–1.83) 1.83 (0.50–1.83)
IL5 2.89 1.44 (0.57–2.85) 1.57 (0.33–2.89)
IL10 1.50 2.67 (1.01–9.04) 1.5 (0.74–2.66)
IL12 3.50 1.85 (0.34–3.5) 2.13 (0.32–3.5)
IL13 4.60 4.6 (1.85–4.69) 4.6 (3.52–6.76)
HGF 73.00 2055.31 (964–6239) 784.041 (508–1189)
TGFβ1 8.73 731.534 (505–1142) 493.514 (375–653)
TGFβ2 265.00 42,209.88 (23,847–98,597) 14,040.62 (10,080–27,262)
TGFβ3 8.37 1535.081 (847–3395) 279.41 (183–395)
Standard curve ranges: IFN-γ, IL2, IL4, IL5, IL10, IL12, IL13 0—2500 pg/mL; HGF, TGFβ1, TGFβ2 0—100.000;
TGFβ3 0—50.000. All values presented in pg/mL.
Table A2. Absolute and relative decline of growth factors over time.
Growth Factor Concentration
(pg/mL)/Time of Collection Raw Concentration (pg/mL) Growth Factor/Protein Ratio
HGF r = −0.39, p < 0.001 ↓ r = −0.19, p = 0.003 ↓
TGFβ1 r = −0.21, p < 0.001 ↓ r = 0.25, p < 0.001 ↑
TGFβ2 r = −0.16, p = 0.01 ↓ r = 0.20, p = 0.004 ↑
TGFβ3 r = −0.35, p < 0.001 ↓ r = −0.06, p = 0.34 ↓
↑—Positive correlation with time of collection; ↓—Negative correlation with time of collection.
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